COVID‐19: Clinical status of vaccine development to date

Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)‐induced COVID‐19 is a complicated disease. Clinicians are continuously facing difficulties to treat infected patients using the principle of repurposing of drugs as no specific drugs are available to treat COVID‐19. To minimize the severit...

Full description

Saved in:
Bibliographic Details
Published in:British journal of clinical pharmacology 2023-01, Vol.89 (1), p.114-149
Main Authors: Kumar, Sunny, Basu, Malini, Ghosh, Pratyasha, Ansari, Aafreen, Ghosh, Mrinal K.
Format: Article
Language:English
Subjects:
clinical research and vaccine efficacy
COVID-19
COVID-19 Vaccines
COVID‐19/SARS‐CoV‐2
Humans
immune responses
production
SARS-CoV-2
vaccination
Vaccine Development
Viral Vaccines - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)‐induced COVID‐19 is a complicated disease. Clinicians are continuously facing difficulties to treat infected patients using the principle of repurposing of drugs as no specific drugs are available to treat COVID‐19. To minimize the severity and mortality, global vaccination is the only hope as a potential preventive measure. After a year‐long global research and clinical struggle, 165 vaccine candidates have been developed and some are currently still in the pipeline. A total of 28 candidate vaccines have been approved for use and the remainder are in different phases of clinical trials. In this comprehensive report, the authors aim to demonstrate, classify and provide up‐to‐date clinical trial status of all the vaccines discovered to date and specifically focus on the approved candidates. Finally, the authors specifically focused on the vaccination of different types of medically distinct populations.
ISSN:0306-5251
1365-2125
DOI:10.1111/bcp.15552